DMD - TREATMENT
Susan T. Iannaccone(Scottish Rite Hospital), Eugenio Mercuri(Università Cattolica del Sacro Cuore), E. Koenig(Sarepta Therapeutics (United States)), Jyoti Malhotra(City Of Hope National Medical Center), Francesco Muntoni(Great Ormond Street Hospital), Baoguang Han(Sarepta Therapeutics (United States)), Eddie Darton(Sarepta Therapeutics (United States)), H. Phan(Rare Disease Therapeutics (United States)), Volker Straub(Newcastle upon Tyne Hospitals NHS Foundation Trust)
Cited by 2
Related Papers
Missense Mutations in the Rod Domain of the Lamin A/C Gene as Causes of Dilated Cardiomyopathy and Conduction-System Disease
|New England Journal of Medicine|1999|1.4k
Improving genetic diagnosis in Mendelian disease with transcriptome sequencing
|Science Translational Medicine|2017|809
Longitudinal effect of eteplirsen versus historical control on ambulation in <scp>D</scp> uchenne muscular dystrophy
|Annals of Neurology|2015|502
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
|Annals of Neurology|2008|466
Mutations in the skeletal muscle α-actin gene in patients with actin myopathy and nemaline myopathy
|Nature Genetics|1999|401